Amneal Pharmaceuticals

FDA approves ready-to-use subcutaneous or intravenous bortezomib for multiple myeloma and mantle cell lymphoma, expected Q2 2025. Reduces pharmacy preparation steps, with individualized dosing and warnings for neuropathy, hypotension, and more.

FDA approves Boruzu, a ready-to-use bortezomib injectable for subcutaneous or IV administration in multiple myeloma and mantle cell lymphoma patients, reducing preparation steps compared to Velcade.

The FDA approved Boruzu, a ready-to-use bortezomib (Velcade) for subcutaneous or intravenous administration, reducing preparation steps. It's a proteasome inhibitor for multiple myeloma and mantle cell lymphoma, referencing Velcade's lyophilized powder. Sean McGowan highlighted the importance of such innovations for oncology providers.

FDA approves Amneal Pharmaceuticals and Shilpa Medicare’s oncology product BORUZU, a ready-to-use bortezomib for subcutaneous administration, simplifying preparation compared to the lyophilised powder form. BORUZU treats multiple myeloma and mantle cell lymphoma, with a planned launch in Q2 2025.

Amneal Pharmaceuticals and Shilpa Medicare announce FDA approval of BORUZU, a bortezomib injection for multiple myeloma and mantle cell lymphoma, set for Q2 2025 launch. BORUZU simplifies administration with a unique J-code and offers a ready-to-use alternative to the current lyophilized powder form. Amneal's Q2 revenues rose 17% to $702 million, with specialty revenues projected to exceed $500 million by 2027, driven by new drug approvals and international expansion.

A new Parkinson’s drug, Crexont, reduces symptoms for 1.5 hours longer than current medications with fewer daily doses, designed by Dr. Robert A. Hauser. The 13-week study involving 630 patients found it more effective, potentially extending relief from tremors, stiffness, and speech difficulties. The drug’s slow-release mechanism allows for longer symptom prevention, improving quality of life for Parkinson’s patients.

Amneal Pharmaceuticals and Shilpa Medicare announce FDA approval of BORUZU, the first ready-to-use bortezomib for subcutaneous administration, to be launched in Q2 2025 for treating multiple myeloma and mantle cell lymphoma.